PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Samsara Inc. (IOT)
33.600.80 (-2.33%)
33.44 - 34.57
31.40 - 61.90
7.61M / 5.95M (Avg.)
-152.73 | -0.22
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.61%
Revenue growth under 50% of CFLT's 3.79%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
2.34%
Gross profit growth at 50-75% of CFLT's 4.31%. Martin Whitman would question if cost structure or brand is lagging.
-21.46%
Negative EBIT growth while CFLT is at 100.00%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-21.46%
Negative operating income growth while CFLT is at 4.35%. Joel Greenblatt would press for urgent turnaround measures.
50.35%
Net income growth above 1.5x CFLT's 23.26%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
52.38%
EPS growth above 1.5x CFLT's 25.93%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
52.38%
Diluted EPS growth above 1.5x CFLT's 25.93%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.99%
Share count expansion well above CFLT's 1.93%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.99%
Diluted share count expanding well above CFLT's 1.93%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
156.52%
Positive OCF growth while CFLT is negative. John Neff would see this as a clear operational advantage vs. the competitor.
142.32%
Positive FCF growth while CFLT is negative. John Neff would see a strong competitive edge in net cash generation.
35.77%
10Y revenue/share CAGR under 50% of CFLT's 255.75%. Michael Burry would suspect a lasting competitive disadvantage.
35.77%
5Y revenue/share CAGR under 50% of CFLT's 255.75%. Michael Burry would suspect a significant competitive gap or product weakness.
35.77%
3Y revenue/share CAGR under 50% of CFLT's 74.69%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
127.09%
10Y OCF/share CAGR above 1.5x CFLT's 42.41%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
127.09%
5Y OCF/share CAGR above 1.5x CFLT's 42.41%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
127.09%
3Y OCF/share CAGR above 1.5x CFLT's 60.49%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
37.87%
Positive 10Y CAGR while CFLT is negative. John Neff might see a substantial advantage in bottom-line trajectory.
37.87%
Positive 5Y CAGR while CFLT is negative. John Neff might view this as a strong mid-term relative advantage.
37.87%
3Y net income/share CAGR 50-75% of CFLT's 51.39%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
-5.83%
Negative equity/share CAGR over 10 years while CFLT stands at 812.90%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-5.83%
Negative 5Y equity/share growth while CFLT is at 812.90%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-5.83%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.06%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
37.20%
Inventory growth of 37.20% while CFLT is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
0.84%
Asset growth above 1.5x CFLT's 0.14%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-0.04%
We have a declining book value while CFLT shows 4.65%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-5.90%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-0.62%
Our R&D shrinks while CFLT invests at 1.64%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
9.02%
SG&A growth well above CFLT's 0.99%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.